Related Experiment Video
Updated: Jul 1, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Longitudinal volumetric analysis of gray matter atrophy in metachromatic leukodystrophy
Murtadha L Al-Saady1,2, Hristina Galabova1,2, Daphne H Schoenmakers1,2,3
1Department of Pediatric Neurology, Amsterdam Leukodystrophy Center, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands.
Abstract:
Metachromatic leukodystrophy (MLD) is an inherited lysosomal storage disorder characterized by arylsulfatase A (ASA) deficiency, leading to sulfatide accumulation and myelin degeneration in the central nervous system. While primarily considered a white matter (WM) disease, gray matter (GM) is also affected in MLD, and hematopoietic stem cell transplantation (HSCT) may have limited effect on GM atrophy. We cross-sectionally and longitudinally studied GM volumes using volumetric MRI in a cohort of 36 (late-infantile, juvenile and adult type) MLD patients containing untreated and HSCT treated subjects. Cerebrum, cortical GM, (total) CSF, cerebellum, deep gray matter (DGM) (excluding thalamus) and thalamus volumes were analyzed. Longitudinal correlations with measures of cognitive and motor functioning were assessed. Cross-sectionally, juvenile and adult type patients (infantiles excluded based on limited numbers) were compared with controls at earliest scan, before possible treatment. Patients had lower cerebrum, cortical GM, DGM and thalamus volumes. Differences were most pronounced for adult type patients. Longitudinal analyses showed substantial and progressive atrophy of all regions and increase of CSF in untreated patients. Similar, albeit less pronounced, effects were seen in treated patients for cerebrum, cortical GM, CSF and thalamus volumes. Deterioration in motor performance (all patients) was related to atrophy, and increase of CSF, in all regions. Cognitive functioning (data available for treated patients) was related to cerebral, cortical GM and thalamus atrophy; and to CSF increase. Our findings illustrate the importance of recognizing GM pathology as a potentially substantial, clinically relevant part of MLD, apparently less amenable to treatment.
Insights
Metachromatic leukodystrophy (MLD) involves gray matter (GM) atrophy, impacting motor and cognitive function. Hematopoietic stem cell transplantation (HSCT) shows limited efficacy in preventing this progressive GM degeneration.
Area of Science:
- Neurology
- Neuroscience
- Genetics
Background:
- Metachromatic leukodystrophy (MLD) is an inherited lysosomal storage disorder caused by arylsulfatase A (ASA) deficiency.
- MLD primarily affects white matter (WM) but also involves gray matter (GM) pathology.
- The impact of hematopoietic stem cell transplantation (HSCT) on GM atrophy in MLD is not fully understood.
Purpose of the Study:
- To investigate gray matter (GM) volume changes in MLD patients using volumetric MRI.
- To assess the cross-sectional and longitudinal progression of GM atrophy in MLD.
- To correlate GM volume changes with cognitive and motor functioning in MLD patients, including those treated with HSCT.
Main Methods:
- Volumetric MRI was used to analyze cerebrum, cortical GM, deep GM (DGM), thalamus, and cerebrospinal fluid (CSF) volumes.
- A cohort of 36 MLD patients (late-infantile, juvenile, adult types) including untreated and HSCT-treated subjects were studied.
- Cross-sectional and longitudinal analyses were performed, correlating imaging findings with clinical assessments.
Main Results:
- MLD patients exhibited reduced cerebrum, cortical GM, DGM, and thalamus volumes compared to controls, with more pronounced effects in adult-type MLD.
- Untreated patients showed progressive atrophy in all GM regions and increased CSF volume.
- HSCT-treated patients displayed similar, though less severe, volumetric changes and CSF increases.
- Motor and cognitive decline correlated with GM atrophy and CSF expansion.
Conclusions:
- Gray matter (GM) pathology is a significant and clinically relevant feature of MLD.
- GM atrophy progresses over time in MLD patients, even after HSCT.
- Current treatments like HSCT may have limited effectiveness in halting GM degeneration in MLD.

